IL6R and inflammatory bowel disease: Recently, a genome-wide meta-analysis of 20,550 patients with CD, 17,647 patients with UC, and more than 40,000 individuals without IBD (controls) indicated that therapeutics designed to block IL-6R signaling might be effective in the treatment of IBD [51].